Therapeutic Progress On Hypereosiophilic Syndromes

As a group of idiopathic diseases of unknown origin,hypereosinophilic syndrome is characterized by eosinophilia in bonemarrow, peripheral blood and tissue usually with multiple-organinvolvement.With the pathogenesis of hypereosiophilic syndromes wereknown progressively, more and more varieties were defined.Clearpathogenesis of HES such as FIP1L1-PDGFRA fusion gene positive HEShas a special efficiency drug-imatinib,and the rest is glucocorticoidmainly.At the same time,new biological agent such as mepolizumab andAlemtuzumab have a promising prospect.